NCT06793319 is a NA clinical trial of educational app in Atrial Fibrillation (AF), sponsored by Kübra Kocaispir.

Who is sponsoring NCT06793319?

NCT06793319 is sponsored by Kübra Kocaispir.

What drugs are being tested in NCT06793319?

Interventions in NCT06793319: educational app.

What condition does NCT06793319 study?

NCT06793319 studies Atrial Fibrillation (AF), Atrial Fibrillation New Onset.

Is NCT06793319 still recruiting?

NCT06793319 is currently completed. Last updated 27 January 2025.

Last reviewed 2025-01-27 · How we verify

NCT06793319

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Education Given to Patients with Atrial Fibrillation on Anxiety Levels

Completed NA Last updated 27 January 2025

What this trial tests

NA trial testing educational app in Atrial Fibrillation (AF) in 60 participants. Completed in 31 October 2024.

Timeline

1 July 2024

Primary endpoint
31 October 2024

31 October 2024

Quick facts

Lead sponsor	Kübra Kocaispir
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	60
Start date	1 July 2024
Primary completion	31 October 2024
Estimated completion	31 October 2024
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

educational app

Conditions studied

Atrial Fibrillation (AF) — all drugs for Atrial Fibrillation (AF) →
Atrial Fibrillation New Onset — all drugs for Atrial Fibrillation New Onset →

Sponsor

Kübra Kocaispir

Who can join

Adults 18 Months to 65 Months, any sex, with Atrial Fibrillation (AF) or Atrial Fibrillation New Onset. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the effect of a structured training program on state anxiety levels in patients diagnosed with Atrial Fibrillation (AF). AF is a chronic heart rhythm disorder that negatively affects patients' quality of life with both physical and psychological symptoms. Lack of information and uncertainty in AF patients cause increased anxiety levels, making compliance with treatment difficult. This study aims to determine whether an educational intervention for AF patients can reduce their anxiety levels and increase their awareness of the disease. This is a randomized controlled trial. A two-session individual training program containing detailed information about AF will be applied to the training group and no training will be given to the control group. Data will be collected through a personal information form and the Situationality Anxiety Inventory (STAI). Hypotheses of the Research H0: Training regarding Atrial Fibrillation has no effect on the anxiety level of patients. H1: Education regarding Atrial Fibrillation reduces the anxiety level of patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation (AF)

Currently open trials in the same condition.

NCT07298473 — Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sp · NA · recruiting
NCT07442175 — Blood Pressure Monitor (TH-75) Atrial Fibrillation Detection Function Clinical Trial · recruiting
NCT07389434 — Feasibility, Safety, Cost-effectiveness, and Environmental Impact of Reprocessed Ablation Catheters in PVI · NA · recruiting
NCT07250529 — Left Bundle Branch Pacing vs Right Ventricular Pacing on AHRE Burden in Patients With Preserved LVEF · NA · recruiting
NCT07358611 — Non-invasive Mapping-Guided Atrial Fibrillation Ablation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06793319 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kübra Kocaispir
Last refreshed: 27 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06793319.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing